Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 481-487

  Shariat, Shahrokh F ^a   Ashfaq, Raheela ^a   Sagalowsky, Arthur I ^a   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

carcinoma; death; disease progression; immunohistochemistry; retinoblastoma; transitional cell

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CELL CYCLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 33846003867     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.09.038     Document Type: Article

References (18)

1. Heney N.M., Ahmed S., Flanagan M.J., Frable W., Corder M.P., Hafermann M.D., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083
2. Lamm D.L., Blumenstein B.A., Crissman J.D., Montie J.E., Gottesman J.E., Lowe B.A., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124
3. Cheng M., Olivier P., Diehl J.A., Fero M., Roussel M.F., Roberts J.M., et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 18 (1999) 1571
4. Tokunaga H., Shariat S.F., Green A.E., Brown R.M., Zhou J.H., Benedict W.F., et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 51 (2001) 16
5. Shariat S.F., Weizer A.Z., Green A., Laucirica R., Frolov A., Wheeler T.M., et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 56 (2000) 735
6. Shariat S.F., Kim J., Raptidis G., Ayala G.E., and Lerner S.P. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61 (2003) 1140
7. Serth J., Kuczyk M.A., Bokemeyer C., Hervatin C., Nafe R., Tan H.K., et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71: (1995) 201
8. Cordon-Cardo C., Zhang Z.F., Dalbagni G., Drobnjak M., Charytonowicz E., Hu S.X., et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57 (1997) 1217
9. Migaldi M., Sgambato A., Garagnani L., Ardito R., Ferrari P., De Gaetani C., et al. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 6 (2000) 3131
10. Sgambato A., Migaldi M., Faraglia B., Garagnani L., Romano G., De Gaetani C., et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59 (1999) 3245
11. Grossman H.B., Liebert M., Antelo M., Dinney C.P., Hu S.X., Palmer J.L., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829
12. Cote R.J., Dunn M.D., Chatterjee S.J., Stein J.P., Shi S.R., Tran Q.C., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58 (1998) 1090
13. Shariat S.F., Tokunaga H., Zhou J., Kim J., Ayala G.E., Benedict W.F., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014
14. Chatterjee S.J., Datar R., Youssefzadeh D., George B., Goebell P.J., Stein J.P., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007
15. Esrig D., Spruck C.H.D., Nichols P.W., Chaiwun B., Steven K., Groshen S., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143 (1993) 1389
16. Cordon-Cardo C., Dalbagni G., Saez G.T., Oliva M.R., Zhang Z.F., Rosai J., et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56 (1994) 347
17. Benedict W.F., Lerner S.P., Zhou J., Shen X., Tokunaga H., and Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18 (1999) 1197
18. Kamai T., Takagi K., Asami H., Ito Y., Oshima H., and Yoshida K.I. Decreasing of p27(Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84 (2001) 1242